Pliva
Pliva is a Croatian generic and biopharmaceutical manufacturer founded in 1921 and wholly-owned by Teva Pharmaceutical Industries, distributing prescription and OTC medicines to patients, healthcare professionals, and institutions across Croatia and Southeast Europe via hospital procurement systems and retail pharmacy networks.
- Company typePrivate
- Founded1921
- HeadquartersZagreb, Croatia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Pliva firmographics
Firmographics- Name
- Pliva
- Legal name
- Pliva
- Website
- https://pliva.com
- Company type
- Private
- Founded year
- 1921
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pliva is a Croatian generic and biopharmaceutical manufacturer founded in 1921 and wholly-owned by Teva Pharmaceutical Industries, distributing prescription and OTC medicines to patients, healthcare professionals, and institutions across Croatia and Southeast Europe via hospital procurement systems and retail pharmacy networks.
- Ownership category
- akta.pro rank
Pliva industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industries
- Generic Hospital & Institutional Products (HLAIABAL), Generic Tender & Government Supply Markets (HLAIABAM)
Keywords
Where Pliva is headquartered
LocationHeadquarters
- HQ city
- Zagreb
- HQ country
- Croatia
- HQ region
- Europe
Offices1 record
Markets served
Pliva business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic Pharmaceutical Sales: Pliva generates revenue through the sale of generic prescription medicines and over-the-counter (OTC) products. The company develops and manufactures generic drugs that treat infections, manage chronic conditions, and improve overall health outcomes for patients globally.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Pliva product offering
Product offeringCore offering
Pliva develops, manufactures, and distributes generic prescription medicines (Naši lijekovi) and over-the-counter pharmaceutical products (Bezreceptni proizvodi) in Croatia and Southeast Europe as part of Teva Pharmaceutical Industries' portfolio. The company focuses on making quality generic and biopharmaceutical medicines accessible and affordable for patients, serving approximately 200 million people globally through Teva's network.
Product overview
Pliva is a Croatian pharmaceutical company operating as part of Teva Pharmaceuticals, focused on generic and biopharmaceutical medications. The company offers prescription medicines (Naši lijekovi) and over-the-counter products (Bezreceptni proizvodi), serving approximately 200 million people globally with daily medication use. Supporting platforms include PLIVAzdravlje for citizen health education and PLIVAmed.net for healthcare professional resources, along with the PhEA mobile application for pharmaceutical events. The product portfolio centers on making quality generic medicines accessible across Croatia and the Southeast Europe region.
Differentiator
Problem solved
Functional benefit
Products and services
- Naši lijekovi (Our Medicines) Prescription pharmaceutical medications for treating various medical conditions, part of Teva's global generic and biopharmaceutical portfolio. Available through pharmacies and hospitals in Croatia and Southeast Europe.
- Bezreceptni proizvodi (Over-the-Counter Products) Non-prescription medications available directly to consumers through retail pharmacy networks for self-medication of minor ailments.
- PLIVAzdravlje Citizen-facing health information platform providing educational content about health conditions, medications, and wellness for patients and the general public.
- PLIVAmed.net Portal for healthcare professionals offering medical information, professional resources, and product content for doctors, pharmacists, and medical staff.
- PhEA - Pharma Event App Mobile application supporting pharmaceutical events with information, networking, and event resources for healthcare professionals.
Companies that use Pliva
Customer profileSegments3 records
Ideal customer profiles2 records
Pliva technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Pliva partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- TevacorePliva is a wholly-owned subsidiary of Teva Pharmaceutical Industries, one of the world's largest generic pharmaceutical companies. The partnership provides Pliva with global scale, R&D capabilities, and access to a portfolio of generic and biopharmaceutical products. Pliva represents Teva's operations in Croatia and Southeast Europe.
Scale indicators2 records
Recent moves5 records
Expansion highlights5 records
Pliva competitors and assessment
Company assessmentDirect peers
- Stada Arzneimittel: German-based European generics and consumer healthcare company. Comparable to Pliva in providing generics, specialty pharma, and OTC products across European markets with a portfolio-led approach to multiple therapeutic categories.
- Krka: Slovenia-based generic pharmaceutical company with a strong Central and Southeast European footprint, offering prescription generics, OTC products, and animal health. Directly comparable to Pliva in regional generics leadership, multi-country CEE/SEE distribution, and integrated manufacturing model.
- Sandoz: Novartis's recently spun-off global generics and biosimilars division, one of the world's largest. Highly comparable as a broad-spectrum generic and biosimilar player with global pipeline depth, operating across European markets where Pliva also competes.
- Viatris: Global generics and specialty pharmaceutical company formed from Mylan and Upjohn. Comparable to Pliva in offering a broad portfolio of off-patent prescription and OTC medicines across multiple European markets, with scale-based cost advantages.
- Zentiva: Czech-headquartered European generics company with strong CEE/SEE presence. Closely comparable to Pliva in regional generics focus, branded-generic positioning, and distribution model across Central and Southeast European markets.
Emerging players
- Hikma Pharmaceuticals: UK-headquartered multinational generics and injectables company expanding its European branded-generics footprint. Comparable to Pliva in offering branded and unbranded generics across multiple therapeutic categories with European distribution.
Regional players
- Alkaloid: North Macedonia-based pharmaceutical manufacturer with regional SEE distribution. Comparable to Pliva in regional generic pharma manufacturing, hospital channel presence, and SEE market coverage in overlapping geographies.
- Alvogen: US-headquartered but with significant Central and Eastern European operations and a generics-plus-brand portfolio. Comparable to Pliva in CEE/SEE generic market presence and portfolio breadth across therapeutic areas.
- Gedeon Richter: Hungarian-headquartered pharmaceutical company with strong CEE presence in branded generics and original research. Comparable to Pliva as a regional Central European pharma champion with hospital-channel distribution and chronic disease portfolio focus.
Broad incumbents
- Teva Pharmaceutical Industries: Pliva's parent company and the world's largest generic pharmaceutical manufacturer. Relevant as both the corporate parent and the broadest incumbent in the global generics category that defines Pliva's competitive context and pipeline.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Pliva social profiles
Digital presencePliva financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pliva leadership team
Management profileNumber of profiles
Pliva funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pliva M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pliva
What does Pliva do?
Pliva develops, manufactures, and distributes generic prescription medicines (Naši lijekovi) and over-the-counter pharmaceutical products (Bezreceptni proizvodi) in Croatia and Southeast Europe as part of Teva Pharmaceutical Industries' portfolio. The company focuses on making quality generic and biopharmaceutical medicines accessible and affordable for patients, serving approximately 200 million people globally through Teva's network.
Is Pliva a public or private company?
Pliva is a private company. It is classified as corporate owned and is currently operating.
When was Pliva founded?
Pliva was founded in 1921. It employs 11 to 50 people.
Where is Pliva based?
Pliva is headquartered in Zagreb, Croatia, in the Europe region.
How does Pliva make money?
One revenue line is on record: generic Pharmaceutical Sales.
Who are Pliva's main competitors?
Direct peers on record are Stada Arzneimittel, Krka, Sandoz, Viatris and Zentiva. Hikma Pharmaceuticals is listed as an emerging player. Regional players are Alkaloid, Alvogen and Gedeon Richter. Teva Pharmaceutical Industries is listed as a broad incumbent.
Does Pliva have an API?
No public API is recorded for Pliva.
What industry is Pliva in?
Pliva's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.